End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Barry I. Freedman, Wake Forest School of Medicine
Carl D. Langefeld, Wake Forest School of Medicine
Kelly K. Andringa, University of Alabama Birmingham
Jennifer A. Croker, University of Alabama Birmingham
Adrienne H. Williams, Wake Forest School of Medicine
Neva E. Garner, University of Alabama Birmingham
Daniel J. Birmingham, Ohio State University
Lee A. Hebert, Ohio State University
Pamela J. Hicks, Wake Forest School of Medicine
Mark S. Segal, University of Florida

Only first 10 authors above; see publication for full author list.

**Journal Title:** Arthritis and Rheumatology  
**Volume:** Volume 66, Number 2  
**Publisher:** Wiley: 12 months | 2014-02, Pages 390-396  
**Type of Work:** Article | Post-print: After Peer Review  
**Publisher DOI:** 10.1002/art.38220  
**Permanent URL:** https://pid.emory.edu/ark:/25593/tw18t  

Final published version: [http://dx.doi.org/10.1002/art.38220](http://dx.doi.org/10.1002/art.38220)

**Copyright information:**  
Copyright © 2014 by the American College of Rheumatology  

*Accessed December 29, 2019 10:13 PM EST*
End-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1

Barry I. Freedman, MD,1 Carl D. Langefeld, PhD,1 Kelly K. Andringa, PhD, MBA,2 Jennifer A. Croker, PhD, MA,2 Adrienne H. Williams, MA,1 Neva E. Garner, MPH,2 Daniel J. Birmingham, PhD,3 Lee A. Hebert, MD,3 Pamela J. Hicks, BS,1 Mark S. Segal, MD, PhD,4 Jeffrey C. Edberg, PhD,2 Elizabeth E. Brown, PhD, MPH, Graciela S. Alarcón, MD, MPH, Karen H. Costenbader, MD, MPH,5 Mary E. Comeau, MA,1 Lindsey A. Criswell, MD, MPH, DSc,6 John B. Harley, MD, PhD,7 Judith A. James, MD, PhD,8 Diane L. Kamen, MD, MSCR,9 S. Sam Lim, MD, MPH,10 Joan T. Merrill, MD,11 Kathy L. Sivils, PhD,11 Timothy B. Niewold, MD,12 Neha M. Patel, MD,13 Michelle Petri, MD, MPH,14 Rosalind Ramsey-Goldman, MD, DrPH,15 John D. Reveille, MD,16 Jane E. Salmon, MD,17 Betty P. Tsao, PhD,18 Keisha L. Gibson, MD, MPH,19 Joyce R. Byers, RN,1 Anna K. Vinnikova, MD,20 Janice P. Lea, MD, MSc,21 Bruce A. Julian, MD,2 and Robert P. Kimberly, MD2 on behalf of the Lupus Nephritis–End-Stage Renal Disease Consortium

1Wake Forest School of Medicine, Winston-Salem, North Carolina 2University of Alabama at Birmingham 3The Ohio State University Wexner Medical Center, Columbus 4University of Florida, Gainesville 5Birmingham Women’s Hospital, Boston, Massachusetts 6University of California, San Francisco 7Cincinnati Children’s Hospital Medical Center and Cincinnati VA Medical Center, Cincinnati, Ohio 8Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City 9Medical University of South Carolina, Charleston 10Emory University School of Medicine, Atlanta, Georgia 11Oklahoma Medical Research Foundation, Oklahoma City 12Mayo Clinic, Rochester, Minnesota 13State University of New York Downstate Medical Center, Brooklyn 14Johns Hopkins School of Medicine, Baltimore, Maryland 15Northwestern University, Feinberg School of Medicine, Chicago, Illinois 16University of Texas

© 2014, American College of Rheumatology

Address correspondence to Barry I. Freedman, MD, or Carl D. Langefeld, PhD, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157 (bfreedma@wakehealth.edu or clangefe@wakehealth.edu); or to Bruce A. Julian, MD, Division of Nephrology, University of Alabama at Birmingham, 1720 Second Avenue South, Birmingham, AL 35294 (bjulian@uab.edu); or to Robert P. Kimberly, MD, Division of Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Shelby Building, Room 172D, 1825 University Boulevard, Birmingham, AL 35294 (rpk@uab.edu).

Drs. Freedman and Langefeld contributed equally to this work. Drs. Julian and Kimberly contributed equally to this work.

Dr. Costenbader has received consulting fees, speaking fees, and/or honoraria from Biogen Idec and Genzyme (less than $10,000 each). Dr. Julian has received consulting fees from Astellas Pharma (less than $10,000).

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Freedman had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Freedman, Langefeld, Croker, Hebert, Hicks, Edberg, Brown, Reveille, Julian, Kimberly.

Acquisition of data. Freedman, Langefeld, Andringa, Croker, Garner, Birmingham, Hebert, Hicks, Segal, Edberg, Brown, Alarcón, Costenbader, Criswell, Harley, James, Kamen, Lim, Merrill, Sivils, Niewold, Patel, Petri, Ramsey-Goldman, Reveille, Salmon, Tsao, Gibson, Byers, Vinnikova, Lea, Julian, Kimberly.

Analysis and interpretation of data. Freedman, Langefeld, Croker, Williams, Hicks, Edberg, Comeau, Sivils, Vinnikova, Julian, Kimberly.
Abstract

Objective—Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that exhibits familial aggregation and may progress to end-stage renal disease (ESRD). LN is more prevalent among African Americans than among European Americans. This study was undertaken to investigate the hypothesis that the apolipoprotein L1 gene \((\text{APOL1})\) nephropathy risk alleles G1/G2, common in African Americans and rare in European Americans, contribute to the ethnic disparity in risk.

Methods—\(\text{APOL1}\) G1 and G2 nephropathy alleles were genotyped in 855 African American SLE patients with LN-ESRD (cases) and 534 African American SLE patients without nephropathy (controls) and tested for association under a recessive genetic model, by logistic regression.

Results—Ninety percent of the SLE patients were female. The mean ± SD age at SLE diagnosis was significantly lower in LN-ESRD cases than in SLE non-nephropathy controls (27.3 ± 10.9 years versus 39.5 ± 12.2 years). The mean ± SD time from SLE diagnosis to development of LN-ESRD in cases was 7.3 ± 7.2 years. The G1/G2 risk alleles were strongly associated with SLE-ESRD, with 25% of cases and 12% of controls having 2 nephropathy alleles (odds ratio \([\text{OR}]\) 2.57, recessive model \(P = 1.49 \times 10^{-9}\), and after adjustment for age, sex, and ancestry admixture (OR 2.72, \(P = 6.23 \times 10^{-6}\)). The age-, sex-, and admixture-adjusted population attributable risk for ESRD among patients with G1/G2 polymorphisms was 0.26, compared to 0.003 among European American patients. The mean time from SLE diagnosis to ESRD development was ~2 years earlier among individuals with \(\text{APOL1}\) risk genotypes \((P = 0.01)\).

Conclusion—\(\text{APOL1}\) G1/G2 alleles strongly impact the risk of LN-ESRD in African Americans, as well as the time to progression to ESRD. The high frequency of these alleles in African Americans with near absence in European Americans explains an important proportion of the increased risk of LN-ESRD in African Americans.

Systemic lupus erythematosus (SLE) is an auto-immune disorder with a markedly increased prevalence among women and among individuals of African ancestry. Genome-wide association studies (GWAS) have identified multiple susceptibility loci for SLE (1–6), as well as for the presence of anti-RNA binding proteins (7) and anti–double-stranded DNA antibodies (8). Lupus nephritis (LN) is a common and potentially severe complication of SLE, which is initiated by immune complex deposition in the renal microvasculature. As with SLE overall, African Americans have a higher prevalence of LN than European Americans (9–11), with lack of equal access to care having often been suggested as a contributing cause of the ethnic disparity in prevalence (12). Familial clustering of LN and LN-associated end-stage renal disease (LN-ESRD) has been observed (13), suggesting that genetic factors contribute not only to the risk of SLE but also to LN-ESRD. Risk alleles in the Fcγ receptor and other genetic regions have been implicated in LN susceptibility (14–16). A subset of individuals with LN ultimately develop progressive nephropathy or ESRD;
thus, factors associated with progressive renal damage are of critical importance and remain unknown.

Two coding alleles in the apolipoprotein L1 gene (APOL1), G1 and G2, are strongly associated with several etiologies of progressive nondiabetic nephropathy in African Americans, including focal segmental glomerulosclerosis (FSGS), human immunodeficiency virus–associated collapsing glomerulopathy (HIVAN), hypertension-attributed ESRD, focal global glomerulosclerosis with interstitial and vascular changes (FGGS), and sickle cell nephropathy; ~12% of African Americans in the general population have 2 risk alleles and are at heightened risk of nephropathy (17–20). These APOL1 alleles are less strongly associated with mild forms of kidney disease (21–23), including LN without progression to ESRD (24,25).

The role of alleles in APOL1 and other genes has not yet been studied in a large sample of African Americans with LN-ESRD. Herein we report the results of a study by a national consortium, in which APOL1-mediated genetic risk for LN-ESRD was compared in a population-based sample of African American SLE cases who were receiving dialysis or had undergone kidney transplantation versus African American SLE patients without nephropathy (controls).

PATIENTS AND METHODS

Study populations

African American subjects with SLE and LN-ESRD were identified through the rheumatology, nephrology, and kidney transplant services of 18 academic referral centers, the Center for Medicare and Medicaid Services, and via a validated query approach using i2b2 (Informatics for Integrating Biology and the Bedside; based at Partners HealthCare System, Boston, MA). Patients with LN-ESRD (cases) had a clinical diagnosis of SLE and were either receiving dialysis or had undergone kidney transplantation. Additionally, cases were required to have World Health Organization class III, IV, or V disease in the native kidney, documented in a biopsy report (reviewed by one of the authors [BIF]) or 2) nephropathy attributed to SLE by a physician based on clinical grounds or prior kidney biopsy, documented in the medical record without an available pathology report. African American controls were drawn from the PROFILE multicenter national consortium cohort and had SLE without proteinuria, abnormal urinary sediment (casts), or renal biopsy evidence of nephropathy (Systemic Lupus International Collaborating Clinics/American College of Rheumatology criteria for kidney involvement) (26).

Genotyping

Two single-nucleotide polymorphisms (SNPs) in the APOL1 G1 nephropathy risk allele (rs73885319 and rs60910145) and an indel for the G2 risk allele (rs71785313) were genotyped in all cases and controls using a custom assay designed at the Wake Forest School of Medicine Center of Genomics and Personalized Medicine on the Sequenom platform. The G1 and G2 genotype calls were visually inspected for quality control.
Statistical analysis

The individuals included in this analysis all passed the quality control analysis for an ongoing GWAS for LN-ESRD, assessed using an Illumina chip (27). Admixture estimates were computed using a linkage disequilibrium–pruned ($r^2 < 0.2$) set of high-quality SNPs (i.e., <5% missing genotype data, no differential missingness between cases and controls, no significant deviation from Hardy-Weinberg equilibrium, no excess heterozygosity), and self-reported and genotypic ancestry were consistent for all individuals in the analyses described herein. Demographic characteristics were compared between LN-ESRD cases and SLE controls using either logistic regression, linear regression, or Wilcoxon’s signed rank test. Compound G1/G2 homozygotes were defined as individuals who were homozygous for the G1 risk allele, homozygous for the G2 risk allele, or heterozygous for the G1 and G2 risk alleles. To test for association between G1/G2 compound risk and LN-ESRD, a logistic regression model was computed, with adjustment for age at SLE onset, sex, and admixture proportion (computed using the program Admixture) (28). The corresponding GWAS adjusted for these admixture estimates and using the same model as reported herein had an inflation factor of 0.99. Thus, after adjustment for these admixture estimates, there is no evidence of inflation of the tests of association. Because information on age at onset of SLE was missing for a subset of cases, the analysis was repeated with adjustment for admixture only; in this analysis the sample size could be maximized and the estimates of effect could be directly compared. To meet the distributional assumptions of conditional normality and homogeneity of variance for linear regression, age at SLE onset and duration from SLE onset to ESRD onset were square root transformed when analyzed as the response variable.

To estimate the crude (unadjusted) attributable risk, we used the standard formula for case-control designs:

\[
\text{Attributable risk} = \frac{n_1 m_0 - n_0 m_1}{m_0 n_1 + m_1 n_0}
\]

where $n_0$ and $n_1$ denote the number of cases without and with the G1/G2 compound risk, respectively, and $m_0$ and $m_1$ denote the number of controls without and with the G1/G2 compound risk, respectively; here, $n_0 + n_1 = n$. The odds ratio (OR)–based population attributable risk (29), using the rare disease assumption, was computed as follows:

\[
\% \text{ population attributable risk} = \frac{b \times (\text{OR} - 1.0)}{b \times (\text{OR} - 1.0) + 1.0}
\]

where $b$ is the estimated proportion of individuals with the G1/G2 compound risk genotype.

RESULTS

The study sample comprised 1,389 African Americans with SLE (855 cases with LN-ESRD and 534 non-nephropathy controls). The proportion of women in the sample was slightly higher among controls than among cases (93% versus 88%; $P = 0.0025$) (Table 1), consistent with the reported increased incidence of LN-ESRD in men (30). Eighty-five
percent of the LN-ESRD cases had received cytotoxic therapy and 9% reported having a first-degree relative with ESRD (data unavailable for SLE non-nephropathy controls). The mean ± SD age at onset of SLE was 27.3 ± 10.9 years and 39.5 ± 12.2 years in cases and controls, respectively ($P = 4.21 \times 10^{-42}$). The mean duration from SLE onset to ESRD onset in cases was 7.3 ± 7.2 years. Among controls, the mean duration from SLE diagnosis to the most recent encounter was 10.1 years.

More than 95% of the LN-ESRD cases had a diagnosis of hypertension. Diagnosis of LN was based on available kidney biopsy report in 571 (66.8%) of the cases and review of medical records in 284 (33.2%).

$APOL1$ G1/G2 genotypes varied based on ESRD status, as shown in Table 2. The African admixture proportion was highest in individuals with 2 copies of the risk alleles for either G1 or G2. Dichotomization of the study population into compound homozygotes for the risk alleles versus heterozygotes and homozygotes for the wild-type allele (i.e., recessive genetic model for risk alleles) revealed a significant association with LN-ESRD (Table 3). Without adjustment for age, sex, and admixture proportion, the logistic model yielded an estimated OR of 2.57 (95% confidence interval 1.89–3.50) for $APOL1$ association with LN-ESRD (recessive model; $P = 1.49 \times 10^{-9}$). Adjustment for these covariates markedly reduced the sample size but still yielded a highly significant association with LN-ESRD. In fact, adjusting only for global measures of European American admixture in these samples increased the magnitude of the effect to an OR of 2.80 and still yielded a highly significant association ($P = 2.21 \times 10^{-8}$), despite reducing the sample size by 26%. Comparison of LN-ESRD cases with and those without available kidney biopsy results revealed no statistically significant differences in the $APOL1$ association ($P = 0.90$); specifically, the OR was 2.46 for LN-ESRD cases without an available kidney biopsy report and 2.54 in cases with a kidney biopsy report.

From these estimates we could compute crude (unadjusted) and OR-based estimates of attributable risk. In the African Americans, the crude estimate of attributable risk was 0.155. Under the rare disease assumption and without adjustment for covariates, the OR-based population attributable risk was 0.195. After adjustment for age, sex, and population admixture estimates, the OR-based population attributable risk was 0.256. The latter increase in the attributable risk estimate is consistent with the increase in the OR from 2.57 to 2.72 with adjustment for admixture estimates. The frequency of the G1/G2 risk genotype is on the order of 0.002 in samples from European Americans. Assuming the same OR (2.72), the same OR-based calculations suggest a G1/G2 attributable risk for LN-ESRD in European Americans to be on the order of 0.0034. These estimates suggest that the attributable risk is ~75 times greater in African Americans than in European Americans, based purely on allele frequency.

If the G1/G2 alleles in $APOL1$ function as a progressor gene for lupus ESRD, one would anticipate that, on average, the time to onset of ESRD would be reduced among individuals with 2 copies of the risk alleles. Our data revealed a 2-year reduction in the time from diagnosis of SLE to the onset of ESRD in this group ($P = 0.01$) (Table 4), representing a 26% shorter mean duration and a 33% shorter median duration compared with patients
having 0 or 1 allele. Specifically, as the number of risk alleles increased, the duration of time from SLE onset to ESRD onset decreased (mean ± SD 8.8 ± 7.8 years, 7.2 ± 6.8 years, and 5.8 ± 6.6 years among patients with no risk allele, 1 risk allele, and 2 risk alleles, respectively; \( P \text{ for trend} = 0.0004 \)). After adjustment for admixture and ESRD status, there was a weak trend toward individuals with 2 G1/G2 risk alleles having a modestly earlier age at SLE diagnosis (\( P = 0.0840 \)).

**DISCUSSION**

To our knowledge, this is the first report of an association between *APOL1* nephropathy risk alleles and severe LN with progression to ESRD in the high-risk African American population. Although a large proportion of patients with SLE develop kidney involvement (hematuria, proteinuria, and/or declining kidney function), most do not progress to development of ESRD. There is strong evidence in support of the notion of an inherited contribution to LN, including far higher rates of LN and LN-ESRD in populations with African ancestry relative to European ancestry, and strong familial aggregation. Delineation of genetic factors that lead to ESRD in patients with LN will likely enrich our understanding of the etiology of progressive LN and improve risk prediction, and may ultimately yield therapeutic targets to prevent progression to end-stage disease.

Because renal damage is one of the main predictors of mortality in SLE, the magnitude of the impact of the *APOL1* G1/G2 alleles on LN-ESRD is very important. The OR-based attributable risk of 0.26 is greater than any individual such estimate for an SLE risk allele, including any individual SNP allele in the major histo-compatibility complex. Given the relative allele frequencies of the G1 and G2 risk alleles across various ethnicities, a large proportion of the ethnic disparity in LN-ESRD burden among individuals of African descent can be attributed to these alleles. Other factors contribute to this disparity as well, but genetic factors, and specifically the *APOL1* alleles, need to be taken into consideration in studies that aim to more accurately characterize additional factors that might be targets for intervention.

The findings reported herein are consistent with the hypothesis that the G1/G2 alleles in *APOL1* accelerate progression to ESRD (31). The difference of 2 years in the median time from diagnosis of SLE to development of ESRD represents an important 33% shorter median time from SLE onset to ESRD development in patients with versus those without the risk G1/G2 genotype. Extensions of these data are relevant with regard to kidney transplantation. The likelihood of donating a kidney to a relative with ESRD as opposed to an unrelated individual is higher among African Americans than among European Americans (32). Kidneys from deceased donors harboring 2 *APOL1* nephropathy alleles have been shown to fail more rapidly after transplantation than those from deceased donors with 0 or 1 risk alleles (33).

Our data revealed that membranous, focal proliferative, and diffuse proliferative forms of LN were more likely to progress to ESRD; only a few patients with the LN–collapsing glomerulopathy lesion (34) were identified in our population-based series. In a previous study of a small number of patients at Wake Forest School of Medicine, we detected...
association of the APOL1 gene with LN-ESRD, which we were unable to replicate after including additional cases with milder (non-ESRD) forms of LN (24). The present study and the study by Larsen et al (34) confirm that the association of alleles of the APOL1 gene with LN is limited to the most aggressive forms that are more likely to progress to ESRD. This is consistent with reports of patients with other nephropathies such as hypertension-attributed disease and in population-based studies of African Americans (20–22).

We elected not to test specific histologic variants or subtypes of LN for an association because renal lesions may change over time, renal biopsies were not interpreted by a single pathologist, and 85% of the LN-ESRD cases had received cytotoxic therapy (treatment may alter the findings on kidney biopsy). The exclusion of cases with physician-reported SLE and ESRD with biopsy evidence of idiopathic FSGS, HIVAN, or other non–SLE-associated kidney diseases from the analysis strengthens the likelihood of a true association. Additionally, the consistent association results in individuals without available kidney biopsy reports support the assumption that LN was the cause of their ESRD. We could not assess the effect of renin–angiotensin–aldosterone system (RAAS) blockade on risk for progression of LN; however, previous studies failed to demonstrate marked improvement in progression of APOL1-associated nephropathy to ESRD with intensive blood pressure control or RAAS inhibition (20).

In conclusion, this large population-based study of African American patients with LN provides strong evidence of an association between LN-ESRD and the APOL1 G1 and G2 nephropathy risk alleles. These findings extend the spectrum of APOL1-associated non-diabetic kidney disease by adding progressive LN to the list that already includes FSGS, FGG (hypertension attributed), HIVAN, and sickle cell nephropathy. Furthermore, our results support the hypothesis that the G1 and G2 alleles of the APOL1 gene mediate progression of LN, as the association with ESRD was stronger than previously described associations with disease that was nonprogressive as manifested by mildly decreased kidney function or modest albuminuria. Although the precise mechanism by which APOL1 contributes to development of severe nephropathy remains unknown, inhibition of the effect of these genetic alleles may assist in slowing progressive renal injury in a broad spectrum of nondiabetic kidney diseases, including LN.

Acknowledgments

Supported by NIH grants R01-DK-070941 and DK-084149 to Dr. Freedman; P01-DK-55546 and UL1-RR-025755 to Dr. Hebert; P60-AR-053308, K24-AR-02175, R01-AR-052300, and UL1-TR-000004 to Dr. Criswell; AI-024717, AI-083194, AR-049084, and AR-042460 to Dr. Harley; U191082714, P30-AR-053483, P30-GM-103510, and U01-AI-101934 to Dr. James and the Oklahoma Medical Research Foundation; P60-AR-062755 and UL1-RR-029882 to Dr. Kamen; R01-AR-060861, K08-AI-083790, P30-DK-42086, L30-AI-071651, and UL1-RR-024999 to Dr. Niewold; R01-AR-043727 to Dr. Petri; K24-AR-002138, P60-AR-30092, and UL1-RR-025741 to Dr. Ramsey-Goldman; R01-AR-043814 to Dr. Tsao; RC2-AR-058951 and UL1-TR-000165 to Dr. Kimberly; P01-AR-049084 to Dr. Kimberly and the PROFILE investigators (Dr. Edberg, Brown, Alarcon, Petri, Ramsey-Goldman, and Reveille); and P01-AI-083194 to the International Consortium on the Genetics of Systemic Lupus Erythematosus (SLEGEN). Additional support was provided by awards from the James D. Casto Research Fund (to Dr. Hebert), the Alliance for Lupus Research (to Drs. Criswell and Niewold), the US Department of Defense (PO094002 to Dr. Harley), the US Department of Veterans Affairs (to Dr. Harley), and the Lupus Research Institute (to Dr. Niewold). Dr. Criswell is recipient of a Kirkland Scholar Award. The Hospital for Special Surgery Registry and Repository is supported by the Mary Kirkland Center for Lupus Research.
The authors thank staff of the Center for Public Health Genomics, Wake Forest School of Medicine for providing computing support, and James Knox for conducting chart review, patient recruitment, and compilation of data from the Birmingham patients.

References


Table 1
Characteristics of the SLE patients with ESRD (cases) and the SLE patients without nephropathy (controls)*

<table>
<thead>
<tr>
<th></th>
<th>LN-ESRD cases (n = 855)†</th>
<th>SLE non-nephropathy controls (n = 534)†</th>
<th>p‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, no. (%)</td>
<td>749 (88)</td>
<td>465 (93)</td>
<td>0.0025</td>
</tr>
<tr>
<td>Age at recruitment, years</td>
<td>41.14 ± 11.66 (41)</td>
<td>41.5 ± 11.73 (42.4)</td>
<td>0.54</td>
</tr>
<tr>
<td>Age at ESRD development, years</td>
<td>33.82 ± 11.57 (33)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Age at SLE onset, years</td>
<td>27.27 ± 10.90 (25)</td>
<td>39.46 ± 12.21 (40)</td>
<td>4.21 ± 10^-42</td>
</tr>
<tr>
<td>Time from SLE onset to ESRD, years</td>
<td>7.33 ± 7.19 (5)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>African ancestry, proportion</td>
<td>0.83 ± 0.09 (0.85)</td>
<td>0.83 ± 0.09 (0.85)</td>
<td>0.61</td>
</tr>
<tr>
<td>No. of ACR SLE criteria (excluding renal criteria) met</td>
<td>4.36 ± 1.74 (4)</td>
<td>4.94 ± 1.07 (5)</td>
<td>1.59 ± 10^-9</td>
</tr>
<tr>
<td>Hypertension, no. (%)</td>
<td>763 (96)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>History of ESRD in first-degree relatives, no. (%)</td>
<td>62 (9)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Cytotoxic therapy, no. (%)</td>
<td>558 (85)</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

* Except where indicated otherwise, values are the mean ± SD (median). SLE = systemic lupus erythematosus; ESRD = end-stage renal disease; LN = lupus nephritis; NA = not applicable or not available; ACR = American College of Rheumatology.

† For some variables, n values were slightly lower due to missing data.

‡ By Wilcoxon’s signed rank test (except for percent female [chi-square test]).
Table 2

Estimated African admixture proportion as a function of number of APOL1 risk alleles

<table>
<thead>
<tr>
<th>APOL1 allele</th>
<th>LN-ESRD cases</th>
<th>SLE non-nephropathy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Risk allele frequency, no. (%)</td>
<td>African admixture proportion, mean ± SD (n)</td>
</tr>
<tr>
<td>WT/WT</td>
<td>279 (33)</td>
<td>0.81 ± 0.10 (234)</td>
</tr>
<tr>
<td>G1/WT</td>
<td>238 (28)</td>
<td>0.83 ± 0.10 (195)</td>
</tr>
<tr>
<td>G2/WT</td>
<td>122 (14)</td>
<td>0.84 ± 0.07 (95)</td>
</tr>
<tr>
<td>G1/G1, G2/G2, or G1/G2</td>
<td>216 (25)</td>
<td>0.86 ± 0.07 (175)</td>
</tr>
</tbody>
</table>

1.2 × 10^−7 0.0001

* WT = wild-type (see Table 1 for other definitions).

† Significance (by Wilcoxon’s signed rank test) of the variation in median African admixture proportion by APOL1 G1/G2 genotype.
### Table 3

Results of test for association between *APOL1* compound risk and LN-ESRD in patients with SLE*

<table>
<thead>
<tr>
<th>Model (n, cases/controls)</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unadjusted (855/534)</td>
<td>2.57 (1.89–3.50)</td>
<td>1.49 × 10⁻⁹</td>
</tr>
<tr>
<td>Adjusted for admixture (699/407)</td>
<td>2.80 (1.95–4.02)</td>
<td>2.21 × 10⁻⁸</td>
</tr>
<tr>
<td>Adjusted for age, sex, and admixture (494/283)</td>
<td>2.72 (1.76–4.19)</td>
<td>6.23 × 10⁻⁶</td>
</tr>
</tbody>
</table>

*Compound risk is coded as a binary variable in which the risk genotypes are as follows: homozygous for the G1 allele, homozygous for the G2 allele, or compound heterozygous for G1/G2 (i.e., 2 copies of any risk allele). The frequency of G1/G2 compound heterozygosity was 0.25 among LN-ESRD cases and 0.12 among SLE non-nephropathy controls. OR = odds ratio; 95% CI = 95% confidence interval (see Table 1 for other definitions).
Table 4

Results of tests for association of the APOL1 G1/G2 risk allele with age at ESRD development, age at SLE onset, and time from SLE onset to ESRD development

<table>
<thead>
<tr>
<th></th>
<th>No admixture adjustment</th>
<th></th>
<th></th>
<th></th>
<th>Admixture adjusted</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0/1 risk alleles</td>
<td>2 risk</td>
<td>alleles</td>
<td></td>
<td>0/1 risk alleles</td>
<td>2 risk</td>
<td>alleles</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0/1 risk alleles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at ESRD development, years</td>
<td>33.9 ± 12.1 (33)</td>
<td>33.5 ± 10.1 (33)</td>
<td>0.9152</td>
<td>33.8 ± 12.0 (32.5)</td>
<td>33.4 ± 10.0 (33)</td>
<td>0.8603</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at SLE onset, years</td>
<td>30.9 ± 12.9 (29)</td>
<td>30.0 ± 11.2 (29)</td>
<td>0.1278</td>
<td>31.3 ± 13.0 (30)</td>
<td>30.4 ± 11.4 (29)</td>
<td>0.0840</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cases</td>
<td>27.0 ± 11.1 (25)</td>
<td>28.1 ± 10.2 (27)</td>
<td>0.1372</td>
<td>27.0 ± 11.1 (25)</td>
<td>28.3 ± 10.3 (27)</td>
<td>0.1554</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>39.4 ± 12.4 (41)</td>
<td>40.0 ± 11.0 (39)</td>
<td>0.6925</td>
<td>39.4 ± 12.4 (41)</td>
<td>40.0 ± 11.0 (39)</td>
<td>0.3268</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time from SLE onset to ESRD development, years</td>
<td>7.89 ± 7.30 (6)</td>
<td>5.81 ± 6.64 (4)</td>
<td>0.0003</td>
<td>7.87 ± 7.33 (6)</td>
<td>5.81 ± 6.06 (4)</td>
<td>0.0111</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Values are the mean ± SD (median). See Table 1 for definitions.